Alzheimer's disease is a progressive neurodegenerative disorder and the most common cause of dementia, primarily affecting older adults. It is characterized by the accumulation of amyloid plaques and tau protein tangles in the brain, leading to gradual memory loss, cognitive decline, behavioral changes, and eventual loss of independent function. First described by Alois Alzheimer in 1906, the disease has no cure, and current treatments focus on symptom management and slowing progression.
1 History and Epidemiology
1.1 Historical milestones
The disease was first identified in 1906 by German psychiatrist and neuropathologist Alois Alzheimer, who reported a case of a 51‑year‑old woman with severe memory loss, language difficulties, and unpredictable behavior. Autopsy revealed abnormal clumps and tangled fibers in her brain. In 1910, Emil Kraepelin named the condition "Alzheimer's disease." For decades, it was considered a rare presenile dementia. The modern understanding of Alzheimer's as a common age‑related condition emerged in the 1970s and 1980s with the development of standardized diagnostic criteria and the discovery of amyloid beta and tau pathology.
1.2 Prevalence and demographics
Alzheimer's disease accounts for 60–80% of all dementia cases. Its prevalence rises sharply with age: approximately 5% of people aged 65–74, 13% of those aged 75–84, and 33% of those aged 85 or older are affected. Women are more likely to develop Alzheimer's than men, partly due to longer life expectancy. The global number of people living with dementia, mostly Alzheimer's, is estimated at over 55 million, a figure projected to nearly triple by 2050 due to population aging.
2 Pathophysiology
2.1 Amyloid hypothesis
The amyloid hypothesis posits that the accumulation of amyloid‑beta (Aβ) peptides into extracellular senile plaques is the initiating event in Alzheimer's disease. Aβ is produced by proteolytic cleavage of the amyloid precursor protein (APP). In Alzheimer's, an imbalance between Aβ production and clearance leads to oligomerization and fibril formation, which trigger synaptic dysfunction, microglial activation, and subsequent tau pathology. This hypothesis has guided most therapeutic development, though its exact causal role remains debated.
2.2 Tau protein and neurofibrillary tangles
Hyperphosphorylated tau protein aggregates into intraneuronal neurofibrillary tangles, a hallmark of Alzheimer's. Under normal conditions, tau stabilizes microtubules. In disease, abnormal phosphorylation causes tau to detach and form paired helical filaments, disrupting axonal transport and leading to neuronal death. Tau pathology spreads through the brain in a predictable pattern, correlating more closely with cognitive decline than amyloid plaques.
2.3 Neuroinflammation and oxidative stress
Chronic neuroinflammation contributes to disease progression. Activated microglia and astrocytes release pro‑inflammatory cytokines and reactive oxygen species, exacerbating neuronal damage. Oxidative stress from mitochondrial dysfunction further promotes Aβ production and tau hyperphosphorylation. These processes create a vicious cycle of neurodegeneration.
2.4 Genetic factors
2.4.1 APOE ε4 allele
The apolipoprotein E ε4 allele is the strongest genetic risk factor for late‑onset Alzheimer's. Carrying one copy increases risk three‑ to four‑fold, and two copies increase risk up to 12‑fold. APOE ε4 accelerates Aβ aggregation and impairs its clearance. Conversely, the ε2 allele appears protective.
2.4.2 Familial Alzheimer's genes (APP, PSEN1, PSEN2)
Mutations in APP, presenilin 1 (PSEN1), and presenilin 2 (PSEN2) cause early‑onset familial Alzheimer's disease, accounting for less than 1% of cases. These mutations alter APP processing, increasing Aβ production or the ratio of longer, more aggregation‑prone Aβ42. Onset typically occurs before age 65, sometimes as early as the 30s.
3 Clinical Presentation and Stages
3.1 Early stage (mild cognitive impairment)
The early stage often involves subtle memory lapses, such as forgetting recent conversations or appointments, misplacing objects, and difficulty finding words. Affected individuals may remain independent in daily activities but notice mild cognitive challenges. Mood changes, anxiety, or depression can occur.
3.2 Middle stage (moderate dementia)
Cognitive decline becomes more pronounced. Memory loss extends to personal history, disorientation to time and place, and difficulty with language and reasoning. Behavioral changes include wandering, agitation, repetitive questioning, and sleep disturbances. Assistance with daily activities such as dressing and grooming becomes necessary.
3.3 Late stage (severe dementia)
In the final stage, individuals lose the ability to communicate, recognize loved ones, and control movement. They become bedridden, require full‑time care, and are vulnerable to infections, particularly pneumonia and urinary tract infections. Swallowing difficulties and weight loss are common.
4 Diagnosis and Assessment
4.1 Clinical criteria and cognitive testing
Diagnosis is primarily clinical, based on history, physical examination, and cognitive assessments. Standardized tests include the Mini‑Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). The National Institute on Aging–Alzheimer's Association (NIA‑AA) diagnostic criteria incorporate biomarkers to increase certainty.
4.2 Neuroimaging
4.2.1 Magnetic resonance imaging (MRI)
MRI reveals patterns of brain atrophy, particularly in the medial temporal lobe, including the hippocampus and entorhinal cortex. It also helps exclude other causes of dementia such as tumors, strokes, or normal‑pressure hydrocephalus.
4.2.2 Positron emission tomography (PET)
PET with amyloid‑binding tracers (e.g., florbetapir) detects Aβ plaques in vivo. Tau‑PET tracers allow visualization of neurofibrillary tangle distribution. FDG‑PET measures cerebral glucose metabolism, showing characteristic hypometabolism in temporoparietal regions.
4.3 Cerebrospinal fluid and blood biomarkers
CSF analysis reveals low Aβ42 levels and high total tau and phosphorylated tau181, reflecting amyloid deposition and neurodegeneration. Blood‑based biomarkers, particularly phosphorylated tau217, are emerging as minimally invasive tools for screening and diagnosis.
5 Treatment and Management
5.1 Pharmacological therapies
5.1.1 Cholinesterase inhibitors
Donepezil, rivastigmine, and galantamine increase acetylcholine levels by inhibiting its breakdown. They provide modest symptom relief in mild‑to‑moderate Alzheimer's, improving cognition and daily function in some patients. Side effects include nausea, vomiting, and diarrhea.
5.1.2 NMDA receptor antagonists
Memantine regulates glutamate activity by blocking NMDA receptors, reducing excitotoxicity. It is used for moderate‑to‑severe Alzheimer's, often combined with cholinesterase inhibitors. Benefits are modest, with minimal side effects.
5.1.3 Emerging disease‑modifying drugs
Aducanumab and lecanemab are monoclonal antibodies targeting aggregated Aβ, approved for early Alzheimer's. They reduce amyloid plaques and modestly slow cognitive decline. Side effects include amyloid‑related imaging abnormalities (ARIA). Further development focuses on tau‑targeting and anti‑inflammatory agents.
5.2 Non‑pharmacological interventions
5.2.1 Cognitive stimulation and rehabilitation
Cognitive training, reality orientation, and reminiscence therapy may help maintain cognitive function and quality of life. Structured activities and social engagement are encouraged. Evidence of long‑term benefit is limited.
5.2.2 Behavioral and environmental modifications
Managing agitation, aggression, and depression involves identifying triggers, maintaining routines, and ensuring a safe, calm environment. Physical activity, music therapy, and caregiver communication techniques can reduce behavioral symptoms.
5.3 Caregiver support and end‑of‑life care
Family caregivers often experience significant stress, depression, and health burden. Support groups, respite care, and counseling are essential. Advance care planning, palliative care, and hospice services address pain, symptom management, and dignity in the final stages.
6 Research and Future Directions
6.1 Prevention studies and lifestyle factors
Observational studies suggest that modifiable risk factors—including hypertension, diabetes, smoking, obesity, physical inactivity, and low education—account for up to 40% of dementia cases. Multidomain interventions (e.g., FINGER trial) target diet, exercise, cognitive training, and vascular risk management to delay cognitive decline. Clinical trials are ongoing.
6.2 Immunotherapy and vaccine development
Active and passive immunotherapies aim to clear amyloid and tau aggregates. While some amyloid‑directed vaccines initially caused meningoencephalitis, newer formulations are safer. Tau‑targeting antibodies are in early trials. Combination therapies may be more effective.
6.3 Ongoing clinical trials and challenges
Current trials explore anti‑tau agents, BACE1 inhibitors (though many failed), anti‑inflammatory drugs, and repurposed medications. Major challenges include high cost of trials, difficulty in recruiting early‑stage participants, lack of validated endpoints, and the need for better biomarkers to monitor disease modification. Promising areas include precision medicine based on genetic profiling and the use of digital cognitive assessments.